Company: NCEL
Filing Date: 2025-02-05
Form Type: F-3
Source: 0001213900-25-010223
Chunk: 84

Company: NewcelX Ltd.
Filing Date: 2025-02-05
Form: F-3
Chunk 84
---
 medical community, and because of that infancy, it may have an adverse effect on its ability to reach potential physicians that are skeptical of the benefits or have questions about the risks, and thus, Kadimastem may run into resistance in the marketing of its products and services. Stem cell therapies may be susceptible to various risks, including side effects, unintended immune system responses, inadequate therapeutic efficacy, and lack of acceptance by physicians, hospital, and the patients themselves.

Kadimastem’s experience and others have shown that physicians are historically slow to adopt new treatment methods based on new technologies, like Kadimastem’s, when existing and trusted methods continue to be supported by established practitioners. Overcoming these obstacles often requires significant marketing expenditures, product performance, cost cutting and/or decreased pricing. It believes the skepticism to be a significant barrier as Kadimastem’s attempts to gain market penetration with its products and services. Failure to achieve market acceptance of its products and services would have a material adverse effect on Kadimastem’s financial condition.

Additionally, part of Kadimastem’s success will depend on continuing to establish and maintain effective strategic partnerships and collaborations with its international partners, which may impose challenges, restrictions, and or financial impacts to its business.

As Kadimastem applies its business strategy of establishing and maintaining strategic relationships, it believes this will allow Kadimastem to expand and complement its products, training, support and commercialization capabilities. Kadimastem believes will allow it to reduce costs with greater economies of scale, and leverage a greater source of market intelligence, with crucial meta data gathered of stem cell therapies applied to a full spectrum across global applications. Notwithstanding, there can be no assurances that Kadimastem will favorably maintain all current or successfully add new relationships to successfully advance its business.

<div align='center'>58</div>

Kadimastem’s likelihood of profitability depends on its ability to license and/or develop and commercialize its products based on its cell production technology, which is currently in the development stage. If Kadimastem is unable to complete the development and commercialization of its cell therapy products successfully, its likelihood of profitability will be limited severely.

Kadimastem is engaged in the business of developing cell therapy products. It has not realized a profit from its operations to date and there is little likelihood that Kadimastem will realize any profits in the short or medium term. Any profitability in the future from its business will be dependent upon successful commercialization of its potential cell therapy products